The Novo Nordisk Foundation is a non-profit institution, whose formal purpose is to provide a stable basis for its company's operations and to make contributions to scientific, humanitarian and social progress.
The vision of The Novo Nordisk Foundation is to contribute
significantly to research and development that improves the health and
welfare of people. Its mission is that its companies create
world-class business results and promote research at universities and
hospitals within the health sciences and biotechnology.
Novo A/S is an unlisted Danish public limited liability company,
owned by the Novo Nordisk Foundation and established to manage the
Foundation's funds and to invest actively in other companies. All A
and B shares in Novo Nordisk A/S, previously held by the Novo Nordisk
Foundation, were transferred to Novo A/S on 31 December 1999. Year-end
2015 Novo A/S represented 27% of the total share capital and 74.5% of
the total number of votes. This figure is not adjusted for Novo
Nordisk A/S' holding of treasury shares.
Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen. Moreover, Novo Nordisk’s ADSs are listed on the New York Stock Exchange. Novo Nordisk’s share capital is DKK 510,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 402,512,800. Novo Nordisk’s A shares are non-listed shares and held by Novo A/S (based in Gladsaxe, Denmark), a private limited Danish company which is 100% owned by the Novo Nordisk Foundation (based in Gentofte, Denmark).
The B shares are issued to the bearer, but may upon request be registered in the holder's name in Novo Nordisk's register of shareholders.
As of 31 December 2015, Novo A/S held a nominal value of DKK 32,762,800 of B share capital. Novo Nordisk's A and B shares are calculated in units of DKK 0.20, each A share carries 200 votes and each B share carries 20 votes.
In March 2016, the Annual General Meeting of the company approved a
reduction of the company's B share capital from DD 412,512,800 to DKK
402,512,800 by cancellation of 50,000,000 B shares of DKK 0.20 each
from the company's own holdings of B shares at a nominal value of DKK
10,000,000, equal to 1.9% of the total share capital. The reduction
of the company's B share capital was implemented on 18 April
This page is intended for members of the UK public
UK/WB/1013/0027(1) February 2017